Flores medical - multisonic - Inhalation mit Ultraschall

Resuscitation

SEVERE PULMONARY HYPERTENSION AND RESUSCITATION

Continuous intravenous prostanoid (e.g. iloprost) therapy is still considered the treatment of choice for patients with severe pulmonary hypertension associated with advanced right-ventricular dysfunction and NYHA IV. According to the German therapy recommendations and approval status (Australia), inhaled iloprost holds an undisputed place also in the treatment of severe pulmonary hypertension. A relatively high portion of patients (40%) with severe pulmonary hypertension, NYHA IV, had been enrolled into a successful proof-of-concept study for inhaled iloprost. Study results published confirm that also high-risk instable patients with PAH may benefit from inhalation administration of iloprost. Both pulmonary haemodynamics as well as physical fitness improved significantly. A few isolated cases demonstrated that patients with known chronic PAH who suffered cardiac arrest in the hospital reached a clinically stable condition after iloprost treatment which was partially given by intravenous bolus administration. It is assumed that this breakthrough reaction prevented circulatory failure after pulmonary artery constriction.